Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration

Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration

BackgroundEmpagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2) and developed as an anti-diabetic agent exerts additional beneficial effects on heart failure outcomes. However, the effect of empagliflozin on vascular cell function and vascular remodeling processes remains largel...

Full description

Bibliographic Details
Main Authors: Jochen Dutzmann, Lena Marie Bode, Katrin Kalies, Laura Korte, Kai Knöpp, Frederik Julius Kloss, Mirja Sirisko, Claudia Pilowski, Susanne Koch, Heiko Schenk, Jan-Marcus Daniel, Johann Bauersachs, Daniel G. Sedding
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
vascular remodeling
neointima formation
restenosis
SGLT2
diabetes
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.956041/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.956041/full

Similar Items